Table 2.
Characteristics of patients undergoing ferumoxytol-enhanced MRI
| Entire cohort (n=217 unique cases) | Anesthesia only (n=94) | Non-anesthesia cases (n=123) | Bolus infusions (n=104) | Slow infusions (n=113) | |
|---|---|---|---|---|---|
| Age (range) | 3d – 94y | 3d – 86y | 12y – 94y | 3d – 94y | 3d – 89y |
| Gender, % female | 43% (n=93) | 45% (n=42) | 41% (n=51) | 40% (n=42) | 45% (n=51) |
| Weight, kg | 50.1 (9.9 – 73.4) | 12.6 (3.6 – 23.0) | 68.5 (52.2 – 81.4) | 59.4 (16.5 – 76.9) | 37.3 (3.2 – 70.4) |
| Creatinine (μmol/L) | 168.0 (61.9 – 282.9) | 53.0 (35.4 – 265.2) | 194.5 (132.6 – 291.7) | 168.0 (70.7 – 265.2) | 168.0 (53.0 – 282.9) |
| eGFR (mL/min/1.73m2) | 31 (18 – 56) | 41 (19 to ≥60) | 29 (18 – 43) | 32 (19 –51) | 28 (17 –58) |
*
Data are reported as median (interquartile range). For adults (age ≥18 years), the eGFR was derived from the MDRD (Modification of Diet in Renal Disease) equation (Levey AS et al. Ann Intern Med. 2009;150(9):604–12). For children (<18 years), the Bedside Schwartz equation was used to calculate eGFR (Schwartz GJ et al. J Am Soc Nephrol. 2009;4(11):1832–43).
**
d, days; eGFR, estimated glomerular filtration rate; y, years